What the business is
Telehealth consultations for COVID antivirals, with hardship-based pricing that makes them free for those who qualify.
Starting capital
$8M led by Lerer Hippeau and Founders Fund
How it started
After Zocdoc, Cyrus Massoumi started Dr. B in New York as an online matchmaking service for unused vaccines, drawing 2.5 million signups.
What happened
Distributed 1.1 million vaccine doses in 90 days; as vaccines became widely available, the company asked how to widen health access and moved into medications, raising $8M for the Paxlovid telehealth pivot.
What has to be true
The pricing tier is the growth engine: hardship approvals create beneficiaries who spread the word instead of a paid acquisition funnel.
It redeems the founder's stated Zocdoc regret — a second company deliberately designed around the first one's miss.
The trim budget is what makes free care economically possible, so mission and unit economics point the same way.
The pivot reuses proven machinery — a matching platform built for scarce vaccines, retargeted at scarce antivirals.
What can be applied
If your differentiator is serving the poor, make it the business model, not the CSR line: every free consult doubles as marketing you don't have to buy.
Aftermath
As of August 2022 Dr. B planned to extend to prescription consultations across heart health, dermatology and reproductive health, all with no-cost options for those who qualify. It faced richly capitalised rivals — Ro at a $6.6 billion valuation, Teladoc's $18.5 billion Livongo deal — and had not planned further fundraising, 'heads down executing' for a busy fall.
FOLLOW THE EVIDENCE